UTHR News and Press, United Therapeutics Corporation From 04/18/23

Results from the EXPEDITE study of Remodulin ® induction prior to Orenitram ® therapy to be presented at ATS Baseline patient data from the TETON studies of Tyvaso ® Inhalation Solution in patients with idiopathic pulmonary fibrosis to be presented at AT...

2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 33 ...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Michael Benkowitz , President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43 rd Annual ...

United Therapeutics Corporation (UTHR) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operat...

United Therapeutics press release ( NASDAQ: UTHR ): Q4 GAAP EPS of $2.67 misses by $1.83 . Revenue of $491.5M (+18.4% Y/Y) misses by $27.7M . Net product sales from our treprostinil-based products (Tyvaso, Remodulin, and Orenitram) grew by $83.5 million, or 23%, in the...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company’s treprostin...

United Therapeutics ( NASDAQ: UTHR ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open. The consensus EPS Estimate is $5.21 (+48.4% Y/Y) and the consensus Revenue Estimate is $519.2M (+25.0% Y/Y). Over the last 2 years, UTHR has bea...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2022 financial results before the market opens on Wednesday, February 22, 2023. United Therapeutics will host a public webcast Wednesday, February 22, 2023, at 9:00 a.m. Eastern...

Summary The market has swiftly priced in United Therapeutics Corporation's patent dispute. The company exhibits strong profitability momentum, with growth coming in at a low cost to earnings. It, therefore, feeds a high percentages of residual free cash flows to shareholders. Ne...